Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634677 | 1.00 | LMNA (0.55) | LMNAHPGDALDH1A1TDP1HSD17B10 | |
| SCHEMBL1317358 | 0.88 | ERN1 (0.49) | LMNAHPGDERN1HSP90AA1TRIM24 | |
| SCHEMBL14070022 | 0.84 | LMNA (0.64) | LMNAHPGDALDH1A1TDP1HSD17B10 | |
| SCHEMBL18138421 | 0.79 | CYP3A4 (0.42) | LMNAHPGDALDH1A1TDP1HSD17B10 | |
| SCHEMBL12834536 | 0.77 | ERN1 (0.63) | ALDH1A1TDP1HSD17B10ERN1 | |
| SCHEMBL2268770 | 0.77 | CYP3A4 (0.56) | ALDH1A1CYP3A4MAPTKMT2AMAPK1 | |
| SCHEMBL31123847 | 0.76 | HPGD (0.56) | LMNAHPGDALDH1A1TDP1HSD17B10 | |
| SCHEMBL14284010 | 0.76 | CYP3A4 (0.50) | LMNAHPGDALDH1A1ERN1CYP3A4 | |
| SCHEMBL1128702 | 0.76 | HPGD (0.56) | LMNAHPGDALDH1A1TDP1HSD17B10 | |
| SCHEMBL23727631 | 0.76 | KDM4E (0.51) | LMNAHPGDALDH1A1TDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2250882-A | — | — | None | — | — | JP | disclosed |
| CN-112996566-B | Chroman-4-one derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-11664093-B2 | Extrapolative prediction of enantioselectivity enabled by computer-driven workflow, new molecular representations and machine learning | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220388972-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2022135136-A1 | TUBERCULATIN ANALOGS AS ANTIVIRAL AGENTS | HONG KONG BAPTIST UNIVERSITY (CN) | 2022-06-30 | — | — | WO | disclosed |
| US-11208419-B2 | Phenylbenzofuran compound, preparation method therefor, composition containing the same and medical application thereof | GUANGXI BOTANICAL GARDEN OF MEDICINAL PLANTS (CN) | 2021-12-28 | — | — | US | disclosed |
| EP-3894004-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-20 | — | — | EP | disclosed |
| US-20210198270-A1 | PHENYLBENZOFURAN COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING THE SAME AND MEDICAL APPLICATION THEREOF | GUANGXI BOTANICAL GARDEN OF MEDICINAL PLANTS (CN) | 2021-07-01 | — | — | US | disclosed |
| CN-112996566-A | Chroman-4-one derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020120642-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040049056-A1 | Process for preparation of esculetin compounds, esculetin compounds and intermediates thereof, and use of both | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1357118-A1 | PROCESS FOR PREPARATION OF ESCULETIN COMPOUNDS, ESCULETIN COMPOUNDS AND INTERMEDIATES THEREOF, AND USE OF BOTH | Kureha Chemical Industry Co., Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-0769015-B1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-03-14 | — | — | EP | disclosed |
| US-5716944-A | USEFUL AS PROPHYLACTIC AND THERAPEUTIC AGENTS OF VARIOUS METABOLIC BONE DISEASES SUCH AS OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0769015-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001267-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-18 | — | — | WO | disclosed |
| JP-H02250882-A | NEW FLUORESCENT LABELING AGENT | DOUJIN KAGAKU KENKYUSHO:KK | 1990-10-08 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | LMNA 3346/4885HPGD 101/4885ALDH1A1 560/4885 |
| US-20040049056-A1 | Process for preparation of esculetin compounds, esculetin compounds and intermediates thereof, and use of both | SUCLG1, SALL4, HSD17B14 | LMNA 2746/4885HPGD 886/4885ALDH1A1 71/4885 |
| US-11208419-B2 | Phenylbenzofuran compound, preparation method therefor, composition containing the same and medical application thereof | WEE1, WEE2, WASF2 | LMNA 1344/4885HPGD 1370/4885ALDH1A1 3452/4885 |
| US-20210198270-A1 | PHENYLBENZOFURAN COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING THE SAME AND MEDICAL APPLICATION THEREOF | WEE1, WEE2, WASF2 | LMNA 1344/4885HPGD 1370/4885ALDH1A1 3452/4885 |
| US-20220388972-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP7A1 | LMNA 724/4885HPGD 1978/4885ALDH1A1 920/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | LMNA 2102/4885HPGD 152/4885ALDH1A1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.